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PPrognostic Markers in Heart Failure
ncremental Predictive Power of B-Type Natriuretic
eptide and Tissue Doppler Echocardiography in the
rognosis of Patients With Congestive Heart Failure
isham Dokainish, MD, FACC, William A. Zoghbi, MD, FACC, Nasser M. Lakkis, MD, FACC,
unice Ambriz, RN, MPH, Rajnikant Patel, MD, Miguel A. Quinones, MD, FACC,
herif F. Nagueh, MD, FACC
ouston, Texas
OBJECTIVES This study was designed to determine how novel indexes of left ventricular (LV) filling
pressure—transmitral early diastolic velocity/tissue Doppler mitral annular early diastolic
velocity (E/Ea) and B-type natriuretic peptide (BNP)—compare to conventional predictors
of outcome in patients with congestive heart failure (CHF).
BACKGROUND It is known that E/Ea can predict LV filling pressure in patients with cardiac disease,
including, in contrast to conventional Doppler indexes, in normal ejection fraction. B-type
natriuretic peptide has also been correlated to LV filling pressure, but appears to provide more
global cardiac information than E/Ea. It is unknown, however, how these novel indexes
compare to conventional predictors of CHF patient outcome.
METHODS A total of 116 consecutive patients hospitalized with CHF underwent simultaneous clinical
assessment, BNP, and comprehensive echo-Doppler study once ready for discharge. The
ability of these variables to determine the primary end point (cardiac death or re-
hospitalization for CHF) was determined.
RESULTS Follow-up was complete on 110 of 116 patients at a mean of 527 days after hospital discharge.
There were 54 patients (50%) with the primary end point (37 re-hospitalizations for CHF
and 17 cardiac deaths). On Cox univariate analysis, E/Ea (chi-square  13.6, p  0.0001)
and BNP (chi-square  17.0, p  0.0001) were significant predictors of the primary end
point. In stepwise analysis, BNP 250 pg/ml and mitral E/Ea 15 had incremental
predictive power (chi-square  23.1, p for increment  0.02), to which conventional
predictors did not add further prognostic information.
CONCLUSIONS In patients admitted to hospital with CHF, pre-discharge BNP and E/Ea are incremental
predictors of outcome, to which conventional predictors do not significantly add. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.025Coll Cardiol 2005;45:1223–6) © 2005 by the American College of Cardiology Foundation
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donventional predictors for congestive heart failure (CHF)
rognosis include clinical variables, two-dimensional echo-
ardiographic parameters (left ventricular [LV] ejection
raction [EF]), and conventional Doppler indexes of LV
lling pressure (mitral inflow) (1). Newer parameters used
n the diagnosis of heart failure include B-type natriuretic
eptide (BNP), a neurohormone secreted from the cardiac
entricles in response to myocyte stretch (2), and transmitral
arly diastolic velocity/tissue Doppler (TD) early diastolic
itral annular velocity (E/Ea), a method of estimating LV
lling pressures (3,4). However, it is unknown how these
ovel indexes compare to conventional predictors of out-
ome in patients with CHF.
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atient population. Consecutive inpatients admitted for
HF were eligible. The diagnosis of CHF was made using
he Framingham criteria (5). After treatment with appro-
riate medications, and within 24 h of hospital discharge as
etermined by the attending physician, subjects underwent
imultaneous (20 min apart) echo-Doppler examination
nd BNP measurement. Patients were excluded if they had
on-sinus rhythm, significant mitral valve disease, unstable
ngina, acute myocardial infarction, or coexisting terminal
iseases.
tudies. BNP DETERMINATION. Two milliliters of venous
lood were placed within 30 min on a Triage BNP test slide
Biosite Diagnostics, San Diego, California) and analyzed
n the Biosite MeterPlus machine.
CHOCARDIOGRAPHY AND DOPPLER. Two-dimensional
easurements were performed according to recommen-
ations of the American Society of Echocardiography (6)
nd indexed to body surface area. Ejection fraction was
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BNP and Tissue Doppler for CHF Prognosis April 19, 2005:1223–6alculated by the multidiameter method. Pulsed Doppler
as used to record transmitral and pulmonary venous
ow in the apical four-chamber view (7). Tissue Doppler
elocities were acquired at the septal and lateral annular
ites and averaged as previously described (3,4). Studies
ere analyzed by an echocardiologist blinded to all
linical data (including patient outcome) and BNP
alues.
ND POINTS AND DEFINITIONS. The primary end point was
he combined risk of cardiac mortality or re-hospitalization
or CHF. Only one event was considered in each patient.
TATISTICAL ANALYSIS. For dichotomous parameters, the
hi-square test was used, and for continuous variables, the
tudent t test was used. Univariate Cox proportional haz-
rds analysis was used to adjust for time-to-event, and
tepwise Cox proportional hazards analysis was used to
etermine the incremental prognostic power of predictors of
utcome, commencing with predictors with the most vari-
bility. Natural log (Ln) transformation was performed on
NP values because of skewed distribution. A p value of
0.05 was significant. Analyses were performed using
igmaStat 3.0 (Chicago, Illinois) and GB Stat 6.5 (London,
nited Kingdom).
ESULTS
rognosis of patients with CHF. Of the 145 patients
dmitted to our institution with a clinical diagnosis of CHF,
16 met the inclusion criteria for the study. Thirteen
atients were excluded for non-sinus rhythm, five for
yocardial infarction, four for unstable angina, four for
oexisting terminal disease, and three for severe mitral
egurgitation. Follow-up was complete on 110 of 116
atients (95%) (mean time from hospital discharge to
ollow-up of 527  47 days). There were 54 of 110 patients
50%) who reached the primary end point (17 cardiac
eaths, 37 re-admissions for CHF). The only difference in
aseline clinical characteristics (Table 1) between patients
ho reached the primary end point and patients who did
ot was an admission to hospital in the preceding year for
HF (45% vs. 18%, respectively, p  0.03).
Abbreviations and Acronyms
AUC  area under curve
BNP  B-type natriuretic peptide
CHF  congestive heart failure
DT  deceleration time
E/Ea  transmitral early diastolic velocity/tissue Doppler
early diastolic annular velocity
EF  ejection fraction
LAVi  left atrial volume index
Ln  natural log
LV  left ventricular
TD  tissue DopplerThe echocardiographic and BNP values in patients with dnd without an event are depicted in Table 2. There were 54
f 110 patients (49%) with an EF 35%, and 69 of 110
atients (63%) with an EF 50%. Mitral E/Ea (19.2  6.5
s. 14.2  6.6, p  0.0003) and BNP (506.2  352.7 vs.
93.3  362.2 pg/ml, p  0.005) were higher in patients
ith an event compared to patients without an event.
In univariate Cox proportional hazards analysis using con-
inuous data, mitral E/Ea (chi-square 13.6, p 0.0001) and
n BNP (chi-square  17.0, p  0.0001) were among the
ignificant predictors of re-hospitalization for CHF or cardiac
eath (Table 3). By receiver-operating characteristic analysis,
/Ea15 (area under curve [AUC] 0.73, p 0.0001) and
NP 250 pg/ml (AUC  0.71, p  0.0001) were the
ptimal cutoffs to predict the primary end point. The Kaplan-
eier curves for E/Ea 15 and BNP 250 pg/ml are
isplayed in Figures 1A and 1B, respectively. Compared to
ndividual echo-Doppler variables, BNP did not have signifi-
antly different predictive power from E/Ea or left atrial
olume index (LAVi) (pNS for both comparisons), but had
igher predictive power than EF (p  0.02) and mitral
eceleration time (DT) (p  0.01).
tepwise analysis for incremental predictive power of
ariables. Having the highest variability for predicting the
rimary end point, BNP 250 pg/ml was applied in the
rst step of multivariate analysis (chi-square  17.0, p 
.001). To this was added the variable with the next highest
ariability, E/Ea 15, resulting in a chi-square of 23.1
p for increment 0.02). The remaining significant predictors
ith highest variability in the dataset (LAVi, TD mitral
nnular late diastolic velocity, EF) did not incrementally
dd to BNP 250 pg/ml plus E/Ea 15.
ISCUSSION
o our knowledge, this is the first study to demonstrate the
ncremental predictive power of pre-discharge BNP and
/Ea in determining CHF patient outcome and to show
hat adding conventional predictors to these novel indexes
able 1. Baseline Characteristics
Variable, n (%)
Event No Event p
Value(n  54) (n  56)
ge (yrs) 58.6  13.0 56.1  11.8 0.30
ender (male) 26 (49) 32 (56) 0.96
iabetes 26 (49) 23 (40) 0.93
ypertension 44 (83) 41 (72) 0.75
urrent smoker 25 (47) 20 (35) 0.76
istory of CHF 35 (66) 22 (39) 0.08
HF admission in previous year 24 (45) 10 (18) 0.03
revious myocardial infarction 14 (26) 12 (21) 0.97
revious angioplasty/stent 2 (0.4) 7 (1.4) 0.61
revious CABG 4 (0.8) 3 (0.5) 0.99
eta-blocker on discharge 26 (50) 30 (53) 0.98
CE inhibitor on discharge 42 (79) 44 (77) 0.90
iuretic on discharge 49 (93) 52 (91) 0.95
igoxin on discharge 7 (14) 9 (15) 0.96
CE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting;
HF  congestive heart failure.oes not significantly increase that power.
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April 19, 2005:1223–6 BNP and Tissue Doppler for CHF PrognosisBeing increased by myocyte stretch, BNP has been
emonstrated to be useful in the diagnosis of CHF (2,3).
lthough previous studies have demonstrated that BNP has
rognostic value in patients with CHF (8), this is the first
tudy to assess the prognostic value of BNP and TD
chocardiography in the same CHF patient population.
owever, there are clinically relevant differences in the
eterminants of E/Ea and BNP: BNP is an excellent marker
f cardiac disease in general, as opposed to LV filling
ressures in specific (3). Conversely, E/Ea appears to be
ore specific for LV filling pressures and less influenced by
Table 2. Echocardiographic Variables and BNP
Variable
Left atrial systolic diameter index (cm/m2)
Left atrial volume index (ml/m2)
LV end-diastolic volume index (ml/m2)
LV mass index (g/m2)
LV ejection fraction (%)
Mitral E/A
Mitral deceleration time (cm/s)
TD mitral systolic velocity (cm/s)
TD mitral early diastolic velocity (cm/s)
TD mitral late diastolic velocity (cm/s)
Mitral E/Ea
Pulmonary venous systolic filling fraction
Pulmonary venous Ar  mitral A duration
Pulmonary artery systolic pressure (mm Hg)
BNP (pg/ml)
A  transmitral late diastolic velocity; Ar  atrial reversal
diastolic velocity; Ea  tissue Doppler early diastolic mitral
able 3. Cox Proportional Hazards Univariate Predictors of
utcome
Continuous Variables
(n  110)
Cox
Proportional
Hazards
Chi-Square
Univariate
p Value
ge 1.3 0.23
iabetes 1.6 0.20
ypertension 2.7 0.10
urrent smoker 1.5 0.23
schemic etiology 0.05 0.83
dmission for CHF in previous year 5.3 0.02
eft ventricular ejection fraction 8.7 0.004
eft atrial systolic dimension index 6.1 0.01
eft atrial volume index 13.2 0.003
eft ventricular end-diastolic volume index 6.7 0.008
eft ventricular mass index 6.2 0.009
ight ventricular fractional area change 6.1 0.01
itral E/A 7.6 0.006
itral deceleration time 6.2 0.01
ulmonary venous Ar  mitral A duration 3.9 0.06
ulmonary venous systolic filling fraction 7.7 0.005
D mitral annular systolic velocity 6.8 0.009
D mitral annular early diastolic velocity 2.9 0.08
D mitral annular late diastolic velocity 11.8 0.006
itral E/Ea 13.6 0.0001
atural log of BNP 17.0 0.0001bbreviations as in Tables 1 and 2.
E
mardiac morphologic variables and right heart hemodynam-
cs (3). Therefore, these two novel indexes may be viewed as
omplementary in their information.
ording to Patient Outcome
Event
 54)
No Event
(n  56) p Value
0  0.8 2.2  0.9 0.001
1  15.7 33.1  13.0 0.0004
2  23.9 75.5  25.3 0.005
4  26.3 89.3  32.8 0.002
0  18.8 45.7  21.6 0.003
6  0.82 1.20  0.78 0.005
7  58.7 207.4  51.5 0.01
2  1.4 5.1  1.5 0.01
8  1.8 5.4  1.5 0.09
3  2.4 6.8  2.1 0.002
2  6.5 14.2  6.6 0.0003
1  0.11 0.49  0.11 0.005
0  34.1 8.8  26.5 0.15
1  11.7 36.5  13.0 0.03
2  352.7 293.3  362.2 0.005
BNP  B-type natriuretic peptide; E  transmitral early
r velocity; LV  left ventricular; TD  tissue Doppler.
igure 1. (A) Transmitral early diastolic velocity/tissue Doppler early
iastolic annular velocity (E/Ea) in patients with congestive heart failure:
aplan-Meier event-free survival. (B) B-type natriuretic peptide (BNP) in
atients with congestive heart failure: Kaplan-Meier event-free survival.acc
(n
3.
43.
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110.
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506./Ea  transmitral peak diastolic velocity/tissue Doppler early diastolic
itral annular velocity.
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BNP and Tissue Doppler for CHF Prognosis April 19, 2005:1223–6The information provided by more conventional predic-
ors of CHF patient outcome (such as EF, DT, and LAVi)
id not significantly add to the predictive power of BNP
lus E/Ea. This is likely because of overlap. For example,
imilar information is provided by LAVi, a marker of
iastolic dysfunction (9), and BNP and E/Ea, both of which
re correlated with LV filling pressures (3). Similarly, mitral
T, a measure of LV filling pressures and ventricular
tiffness (2), could be expected to have overlap with E/Ea
nd BNP. Finally, BNP has been demonstrated to be
levated in patients with depressed EF, independent of LV
lling pressures (4).
linical implications. A clinical algorithm for predicting
HF patient outcome is displayed in Figure 2, commencing
ith pre-discharge BNP and, if 250 pg/ml, followed by
etermination of E/Ea.
tudy limitations. This study included 116 patients, but
espite the sample size, there was a high event rate (50%).
he study population was relatively young, with a high
igure 2. Clinical algorithm to predict patient outcome using B-type
atriuretic peptide (BNP) and tissue Doppler imaging. E/Ea transmitral
eak diastolic velocity/tissue Doppler early diastolic mitral annular velocity.revalence of hypertension and diabetes; thus, the resultseed to be validated prospectively in other populations.
ptimally, patients would undergo echo-Doppler and BNP
mmediately at hospital admission, then repeated once
reated and stabilized. In the current study, only the latter
as performed owing to financial and clinical constraints.
hus, the response of BNP and TD indexes to therapy
ould not be assessed and would be of interest in further
tudies.
onclusions. In patients hospitalized for CHF, pre-
ischarge BNP- and TD-derived mitral E/Ea are powerful
nd incremental predictors of cardiac death or re-
ospitalization for CHF, to which conventional predictors
f outcome do not significantly add.
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